Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$3.24 USD
+0.09 (2.86%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $3.23 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -292.31 | -237.11 | -166.09 | -118.55 | -46.38 |
Depreciation/Amortization & Depletion | -11.77 | -2.30 | 1.45 | 0.72 | 0.11 |
Net Change from Assets/Liabilities | 5.86 | 13.25 | 16.56 | 7.84 | 6.51 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 90.39 | 62.41 | -6.01 | 23.16 | 0.62 |
Net Cash From Operating Activities | -207.82 | -163.75 | -154.09 | -86.83 | -39.14 |
Property & Equipment | -0.58 | -2.55 | -6.11 | -0.76 | -0.35 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -43.87 | -111.63 | 2.31 | -284.07 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | -14.32 | 0.00 | 0.00 |
Net Cash from Investing Activities | -44.46 | -114.18 | -18.12 | -284.83 | -0.35 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 237.30 | 261.04 | 179.67 | 342.02 | 81.88 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | -1.15 | 18.42 | -0.05 |
Net Cash from Financing Activities | 237.30 | 261.04 | 178.52 | 360.44 | 81.83 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -14.98 | -16.89 | 6.31 | -11.22 | 42.34 |
Cash at Beginning of Period | 45.70 | 62.58 | 56.27 | 67.49 | 25.15 |
Cash at End of Period | 30.72 | 45.70 | 62.58 | 56.27 | 67.49 |
Diluted Net EPS | -4.47 | -4.48 | -3.72 | -4.19 | NA |
Fiscal Year End for Zentalis Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.24 | 10.04 | -292.31 | -231.37 | -175.83 |
Depreciation/Amortization & Depletion | -4.31 | -2.44 | -11.77 | -7.55 | -5.78 |
Net Change from Assets/Liabilities | -2.21 | -16.31 | 5.86 | -4.40 | -9.18 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -2.36 | -43.27 | 90.39 | 76.10 | 62.23 |
Net Cash From Operating Activities | -87.11 | -51.97 | -207.82 | -167.22 | -128.56 |
Property & Equipment | -0.16 | -0.04 | -0.58 | -0.41 | -0.32 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 96.19 | 61.59 | -43.87 | -1.99 | 115.37 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 96.04 | 61.55 | -44.46 | -2.40 | 115.05 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.26 | 0.25 | 237.30 | 237.30 | 236.99 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.24 | -0.24 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.02 | 0.01 | 237.30 | 237.30 | 236.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 8.94 | 9.58 | -14.98 | 67.68 | 223.49 |
Cash at Beginning of Period | 30.72 | 30.72 | 45.70 | 45.70 | 45.70 |
Cash at End of Period | 39.66 | 40.30 | 30.72 | 113.38 | 269.19 |
Diluted Net EPS | -1.24 | 0.14 | -0.76 | -0.79 | -1.85 |